Multi‐Gene Pharmacogenomic Testing in a Community‐Based Setting Is Feasible and Reduces Total Healthcare Costs
Clinical and Translational Science · 2025-12 · 18 (12)
DOI: 10.1111/cts.70418 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 27.11.2025. Verfasst von Nihal El Rouby und 15 weiteren Autor:innen. Beteiligte Einrichtung: St Elizabeth Healthcare, Edgewood, Kentucky, USA. Hauptthemen laut MEDLINE: Pharmacogenomic Testing, Health Care Costs, Community Health Services. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pharmacogenomic (PGx) testing using multi‐gene panels (mgPGx) is documented to improve clinical outcomes; however, real‐world data on its economic impact remain limited. This study aimed to evaluate the utility and economic value of mgPGx testing among Medicare patients within a community‐based health system. We identified Medicare Advantage patients within the primary care setting of a community‐based health system hospital who were taking ≥ 1 PGx‐guided medication using a stratification algorithm. In total, 1042 patients participated in mgPGx testing. We evaluated the prevalence of PGx medications, polypharmacy involving PGx medications, and actionable results (i.e., a phenotype with PGx guidance and a relevant PGx medication). A Total Cost of Care (TCOC) analysis was performed for a subset of patients ( n = 548) who underwent PGx testing and were matched to a control group that did not undergo PGx testing using propensity score matching. Total medical expenses over 12 months, both before and after testing, were compared. Forty‐four percent ( n = 454/1042) of patients were ≥ 3 PGx‐guided medications. Over one‐third of patients who were on ≥ 3 PGx medications had ≥ 2 actionable results (35.5%, n = 161/454). The TCOC analysis demonstrated a trend toward a net cost savings of $1827 per member per year (PMPY), with $1582 in medical savings and $245 in pharmacy savings. Polypharmacy with PGx medications is prevalent, and mgPGx led to cost savings. Further research with a larger sample size is needed to replicate the results and assess the long‐term impact on healthcare utilization and costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- St Elizabeth Healthcare, Edgewood, Kentucky, USA.
- Division of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA.
- OneOme, Minneapolis, Minnesota, USA.
- Humana, Louisville, Kentucky, USA.
ORCID-Profile: Nihal El Rouby, Josiah D Allen, Carley Brueckner
Zitieren
APA
El Rouby, N., Allen, J. D., Koep, T., McIntyre, P., Kelly, J., Ramesh, A., Desai-Naik, A., Chiang, J., Patel, S., Brueckner, C., Crider, A., Miller, G., Schumann, A., Wallace, J., Wendt, B., & Grund, J. (2025). Multi‐Gene Pharmacogenomic Testing in a Community‐Based Setting Is Feasible and Reduces Total Healthcare Costs. Clinical and Translational Science, 18(12). https://doi.org/10.1111/cts.70418
Vancouver
El Rouby N, Allen JD, Koep T, McIntyre P, Kelly J, Ramesh A, et al. Multi‐Gene Pharmacogenomic Testing in a Community‐Based Setting Is Feasible and Reduces Total Healthcare Costs. Clinical and Translational Science. 2025;18(12). doi:10.1111/cts.70418
BibTeX
@article{ElRouby2025,
author = {El Rouby, Nihal and Allen, Josiah D and Koep, Tyler and McIntyre, Pat and Kelly, James and Ramesh, Adarsh and Desai-Naik, Anita and Chiang, Jonathan and Patel, Sheena and Brueckner, Carley and Crider, Anna and Miller, Grace and Schumann, Andrea and Wallace, Jody and Wendt, Barry and Grund, Jaime},
title = {Multi‐Gene Pharmacogenomic Testing in a Community‐Based Setting Is Feasible and Reduces Total Healthcare Costs},
journal = {Clinical and Translational Science},
year = {2025},
volume = {18},
number = {12},
doi = {10.1111/cts.70418}
}
EUVIMED